Tharimmune, Inc. announced on March 24, 2025, positive preclinical results for its novel oral antibody, TH023. This program targets Tumor Necrosis Factor-alpha (TNF-α), a key mediator in inflammatory conditions.
In a murine model, a proprietary protease enzyme stabilized platform demonstrated successful oral delivery of infliximab, a TNF-α inhibitor. Detected serum concentrations were significantly higher than the standard serum trough concentration needed for antibody efficacy in immunology indications via injection, which is typically around 3-5µg/ml.
This breakthrough could fulfill the promise of delivering a safe and effective oral antibody medication against inflammation. It offers a significant advantage in patient convenience and compliance over existing injectable biologics, potentially revolutionizing treatment paradigms.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.